Kars T U, Kulaksızoğlu M, Kılınç I
Department of Internal Medicine, Necmettin Erbakan University Meram School of Medicine, Konya, Turkey.
Division of Endocrinology and Metabolism Disease, Department of Internal Medicine, Necmettin Erbakan University Meram School of Medicine, Meram, Konya, Turkey.
Endocr Oncol. 2021 Jun 9;1(1):17-22. doi: 10.1530/EO-21-0005. eCollection 2021 Jan.
Thyroid cancer can be detected in 5-10% of patients with thyroid nodules. Management may be a challenge if fine-needle aspiration biopsy yields Bethesda III findings. Most of these cases undergo surgery and are ultimately found benign. Our aim was to evaluate whether serum osteopontin can accurately estimate thyroid cancer risk in cases with cytologically Bethesda III thyroid nodules and, thereby, decrease the number of unnecessary surgical interventions.
We obtained blood samples of cases with repeated cytologically Bethesda III thyroid nodules before surgery, and followed up the pathology results after thyroidectomy. We evaluated serum osteopontin from 36 patients with papillary thyroid cancer and compared them with 40 benign cases.
Serum osteopontin levels in patients with papillary thyroid cancer are significantly higher than in benign cases (mean serum osteopontin: 10.48 ± 3.51 ng/mL vs6.14 ± 2.29 ng/mL, < 0.001). The area under the receiver operating characteristics curve was 0.851, suggesting that serum osteopontin could have considerable discriminative performance.
In our preliminary study, high serum osteopontin levels can predict the risk of papillary thyroid cancer in thyroid nodules with Bethesda III cytology. Further studies are necessary to confirm these findings.
甲状腺结节患者中5%-10%可检测出甲状腺癌。如果细针穿刺活检结果为贝塞斯达Ⅲ级，治疗可能会面临挑战。这些病例大多接受手术，最终被发现为良性。我们的目的是评估血清骨桥蛋白是否能准确估计细胞学检查为贝塞斯达Ⅲ级甲状腺结节患者的甲状腺癌风险，从而减少不必要的手术干预数量。
我们获取了术前细胞学检查反复为贝塞斯达Ⅲ级甲状腺结节患者的血样，并在甲状腺切除术后随访病理结果。我们评估了36例甲状腺乳头状癌患者的血清骨桥蛋白，并将其与40例良性病例进行比较。
甲状腺乳头状癌患者的血清骨桥蛋白水平显著高于良性病例（血清骨桥蛋白均值：10.48±3.51 ng/mL对6.14±2.29 ng/mL，<0.001）。受试者工作特征曲线下面积为0.851，表明血清骨桥蛋白具有相当的鉴别性能。
在我们的初步研究中，血清骨桥蛋白水平升高可预测细胞学检查为贝塞斯达Ⅲ级甲状腺结节患者的甲状腺乳头状癌风险。需要进一步研究来证实这些发现。
